ArticleScientific reports2026
Cytotoxic activity of marine derived bioactive compounds from red sea sponges supported by LC-MS/MS profiling and molecular docking.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Marine sponges are prolific sources of structurally diverse secondary metabolites with notable pharmacological potential. This study aimed to explore and compare the chemical composition and cytotoxic activity against liver cancer cells of three Red Sea sponge species—Stylissa carteri, Hemimycale arabica, and Negombata magnifica—collected from distinct ecological sites. Sequential solvent extraction was conducted using n-hexane, ethyl acetate, and n-butanol, followed by phytochemical screening, and LC–MS/MS-based metabolite profiling. Cytotoxicity was evaluated through MTT assay, colony formation, and wound healing (scratch) assay against HepG2 liver cancer cells. Molecular docking was carried out using the Chk2 kinase receptor to assess binding affinities and interaction modes of the identified metabolites. The total MeOH:DCM extract of S. carteri (El Gouna) showed potent cytotoxicity, with an IC50 of 37 µg/mL, 80% growth inhibition in the MTT assay, and significant suppression of colony formation (20.3 ± 2.1% survival) and cell migration (35.4 ± 2.1% wound closure). LC–MS/MS analysis tentatively identified pyrrole–imidazole alkaloids, including hymenialdisine, oroidin, and spongiacidin D. Docking revealed strong binding affinities of hymenialdisine (− 8.35 kcal/mol) and spongiacidin D (− 7.30 kcal/mol) with key Chk2 active-site residues. MD simulations indicated that the hymenialdisine–Chk2 complex maintained stability throughout 100 ns, with reduced RMSD (2.54 ± 0.48 Å), RMSF (1.46 ± 0.14 Å), Rg (20.70 ± 0.17 Å), and SASA (13,916 Å2) compared to the Apo protein, confirming a rigid and stable ligand–protein interaction. MM/GBSA calculations revealed a favorable total binding free energy (ΔG_bind = − 33.17 ± 0.17 kcal/mol), dominated by van der Waals and electrostatic contributions. ADMET predictions indicated compliance with Lipinski and Veber rules, suggesting good oral bioavailability. S. carteri from El Gouna is enriched in bioactive brominated alkaloids that exhibit potent cytotoxic activity against HepG2 cells. Integration of cytotoxic assays, LC–MS/MS profiling, docking, and MD simulations underscores the influence of species and environmental conditions on sponge-derived bioactivity. These findings provide a strong rationale for advancing S. carteri metabolites, especially hymenialdisine and spongiacidin D as potential cytotoxic agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.